Patents by Inventor Tohru Minamino

Tohru Minamino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENT FOR ELIMINATING SENESCENT CELLS
    Publication number: 20240009167
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 11, 2024
    Applicants: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru MINAMINO
  • Agent for eliminating senescent cells
    Patent number: 11813244
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: November 14, 2023
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • IMMUNITY INDUCER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AGING-RELATED DISEASES
    Publication number: 20220267374
    Abstract: An immunity inducer contains, as an active ingredient, any of a peptide (a) or (b) below, or an expression vector having a structural gene including a region encoding the peptide. (a) A peptide including an amino acid sequence represented by SEQ ID NO: 1 or 2; (b) a peptide having immunity induction activity and including an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2. A pharmaceutical composition for preventing or treating aging-related diseases includes the immunity inducer and an adjuvant.
    Type: Application
    Filed: July 7, 2020
    Publication date: August 25, 2022
    Applicant: Juntendo Educational Foundation
    Inventors: Tohru MINAMINO, Hironori NAKAGAMI
  • AGENT FOR ELIMINATING SENESCENT CELLS
    Publication number: 20210236461
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Application
    Filed: January 7, 2021
    Publication date: August 5, 2021
    Applicants: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru MINAMINO
  • Agent for eliminating senescent cells
    Patent number: 11007172
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 18, 2021
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • AGENT FOR ELIMINATING SENESCENT CELLS
    Publication number: 20190192482
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Application
    Filed: August 29, 2017
    Publication date: June 27, 2019
    Applicants: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru MINAMINO
  • DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP
    Publication number: 20130310321
    Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 21, 2013
    Applicants: DAIICHI PURE CHEMICALS CO., LTD.
    Inventors: Masao DAIMON, Tohru Minamino, Kenji Hashimoto, Issei Komuro
  • DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP
    Publication number: 20120122777
    Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.
    Type: Application
    Filed: June 16, 2011
    Publication date: May 17, 2012
    Applicants: Masao Daimon, DAIICHI PURE CHEMICALS CO., LTD.
    Inventors: Masao DAIMON, Tohru MINAMINO, Kenji HASHIMOTO, Issei KOMURO
  • Diagnostic Agent For Ischemic Heart Disease Risk Group
    Publication number: 20080146498
    Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.
    Type: Application
    Filed: March 2, 2005
    Publication date: June 19, 2008
    Applicants: Daiichi Pure Chemicals Co., Ltd.
    Inventors: Masao Daimon, Tohru Minamino, Kenji Hashimoto, Issei Komuro